Design Therapeutics Inc
NASDAQ:DSGN
Cash Flow Statement
Cash Flow Statement
Design Therapeutics Inc
Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | |||||||||||
Net Income |
(22)
|
(36)
|
(43)
|
(51)
|
(57)
|
(63)
|
(69)
|
(74)
|
(72)
|
(67)
|
|
Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
Stock-Based Compensation |
3
|
5
|
6
|
8
|
9
|
11
|
12
|
13
|
13
|
0
|
|
Other Non-Cash Items |
3
|
5
|
7
|
8
|
9
|
10
|
9
|
9
|
8
|
7
|
|
Cash Interest Paid |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Change in Working Capital |
3
|
1
|
(1)
|
3
|
2
|
2
|
3
|
4
|
3
|
1
|
|
Cash from Operating Activities |
(16)
N/A
|
(29)
-82%
|
(38)
-28%
|
(40)
-6%
|
(45)
-14%
|
(51)
-13%
|
(57)
-11%
|
(60)
-6%
|
(61)
-1%
|
(59)
+4%
|
|
Investing Cash Flow | |||||||||||
Capital Expenditures |
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
|
Other Items |
36
|
(52)
|
(75)
|
(210)
|
(269)
|
(220)
|
(201)
|
(32)
|
46
|
53
|
|
Cash from Investing Activities |
35
N/A
|
(54)
N/A
|
(76)
-42%
|
(212)
-178%
|
(270)
-28%
|
(221)
+18%
|
(202)
+9%
|
(33)
+84%
|
46
N/A
|
53
+14%
|
|
Financing Cash Flow | |||||||||||
Net Issuance of Common Stock |
334
|
379
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
|
Net Issuance of Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
|
Cash from Financing Activities |
334
N/A
|
379
+13%
|
0
-100%
|
0
-56%
|
0
+76%
|
0
-20%
|
0
-67%
|
1
+525%
|
0
-30%
|
1
+107%
|
|
Change in Cash | |||||||||||
Net Change in Cash |
353
N/A
|
296
-16%
|
(113)
N/A
|
(251)
-122%
|
(315)
-25%
|
(272)
+14%
|
(259)
+5%
|
(92)
+64%
|
(15)
+84%
|
(5)
+64%
|
|
Free Cash Flow | |||||||||||
Free Cash Flow |
(17)
N/A
|
(31)
-78%
|
(39)
-26%
|
(41)
-6%
|
(46)
-12%
|
(52)
-12%
|
(58)
-11%
|
(61)
-5%
|
(61)
-1%
|
(59)
+4%
|